Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NUVL

Nuvalent Inc

Dec 11 • 04:00PM ET

93.61

Dollar change +0.65
Percentage change 0.70	%

Healthcare • Biotechnology • USA • NASD

Peers: ARQT ABUS TIL ALLO BEAM IMTX KRYS RGNX DTIL

| Held by: VTI IWM VB VBR VXF XBI IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.48	Insider Own	41.01%	Shs Outstand	65.50M	Perf Week	-0.65%
Market Cap	6.65B	Forward P/E	-	EPS next Y	-4.50	Insider Trans	-7.14%	Shs Float	41.91M	Perf Month	-0.83%
Income	-224.28M	PEG	-	EPS next Q	-1.07	Inst Own	65.53%	Short Float	12.12%	Perf Quarter	14.61%
Sales	0.00M	P/S	-	EPS this Y	-81.22%	Inst Trans	6.55%	Short Ratio	9.77	Perf Half Y	16.98%
Book/sh	15.81	P/B	5.92	EPS next Y	-14.33%	ROA	-27.79%	Short Interest	5.08M	Perf Year	31.60%
Cash/sh	16.44	P/C	5.69	EPS next 5Y	-	ROE	-29.57%	52W Range	61.79 - 113.51	Perf YTD	27.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.54%	ROI	-20.01%	52W High	-17.53%	Beta	1.31
Dividend TTM	-	Quick Ratio	23.07	Sales past 5Y	0.00%	Gross Margin	-	52W Low	51.48%	ATR (14)	3.07
Dividend Ex-Date	-	Current Ratio	23.07	EPS Y/Y TTM	-71.14%	Oper. Margin	-	RSI (14)	48.98	Volatility	2.99% 3.19%
Employees	92	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.31	Target Price	115.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-117.92%	Payout	-	Rel Volume	0.57	Prev Close	92.96
Sales Surprise	-	EPS Surprise	-37.03%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	519.61K	Price	93.61
SMA20	0.54%	SMA50	-2.23%	SMA200	13.63%	Trades		Volume	298,375	Change	0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Neutral	$100
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Show Previous Ratings

Dec-09-24 06:30AM	Nuvalent Appoints Grant Bogle to Board of Directors (PR Newswire)
Nov-26-24 06:52AM	Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-12-24 06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results (PR Newswire)
Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Loading…
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
04:52AM	Loading…
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Loading…
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)
Aug-31-23 06:30AM	Nuvalent to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace)
Aug-10-23 06:30AM	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 06:30AM	Nuvalent to Participate in Upcoming August Investor Conferences (PR Newswire)
Jul-21-23 08:50AM	Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why (Zacks)
Jun-07-23 08:50AM	Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 06:30AM	Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (PR Newswire)
May-11-23 06:30AM	Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-19-23 06:30AM	Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days (PR Newswire) +5.13%
Apr-18-23 09:00AM	Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 (PR Newswire)
Apr-02-23 10:56AM	Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Mar-23-23 06:30AM	Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) (PR Newswire)
Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 (PR Newswire) +6.05% -6.24%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? (Zacks)
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 (PR Newswire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going (Zacks)
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire) -6.04% +5.13%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire) -5.63%
07:15AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial (American City Business Journals) +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win (Investor's Business Daily)
11:10AM	Why Nuvalent Shares Are Surging 45% Today? (Benzinga)
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC (PR Newswire)
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 (PR Newswire)
Oct-23-22 09:26AM	We Think Nuvalent (NASDAQ:NUVL) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Oct-17-22 06:30AM	Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium (PR Newswire) +6.99%
Oct-06-22 06:30AM	Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BCIP Life Sciences Associates,	Affiliate	Dec 11 '24	Proposed Sale	93.61	135,714	12,704,188		Dec 11 09:14 PM
Bain Capital Life Sciences Fun	Affiliate	Dec 11 '24	Proposed Sale	93.61	1,114,286	104,308,312		Dec 11 09:13 PM
Balcom Alexandra	Chief Financial Officer	Nov 29 '24	Option Exercise	27.85	10,000	278,500	43,300	Dec 03 04:46 PM
Balcom Alexandra	Chief Financial Officer	Nov 29 '24	Sale	95.79	10,000	957,940	33,300	Dec 03 04:46 PM
Shair Matthew	Director	Nov 25 '24	Sale	96.22	2,000	192,443	222,522	Nov 27 04:48 PM
Matthew Shair	Director	Nov 25 '24	Proposed Sale	96.45	8,000	771,600		Nov 25 04:12 PM
Porter James Richard	President and CEO	Nov 15 '24	Option Exercise	27.85	27,000	751,950	215,113	Nov 19 04:45 PM
Porter James Richard	President and CEO	Nov 15 '24	Sale	87.94	27,000	2,374,479	188,113	Nov 19 04:45 PM
Noci Darlene	Chief Development Officer	Nov 01 '24	Option Exercise	14.40	5,000	72,000	38,300	Nov 04 04:49 PM
Noci Darlene	Chief Development Officer	Nov 01 '24	Sale	88.60	5,000	442,980	33,300	Nov 04 04:49 PM
Balcom Alexandra	Chief Financial Officer	Oct 31 '24	Option Exercise	27.85	10,000	278,500	43,300	Nov 04 04:46 PM
Balcom Alexandra	Chief Financial Officer	Oct 31 '24	Sale	89.19	10,000	891,879	33,300	Nov 04 04:46 PM
Shair Matthew	Director	Oct 28 '24	Sale	91.73	2,000	183,468	224,522	Oct 30 04:46 PM
Flynn James E	Director	Oct 22 '24	Sale	97.75	2,000,000	195,500,000	8,670,512	Oct 24 04:08 PM
Deerfield Healthcare Innovatio	Stockholder	Oct 22 '24	Proposed Sale	101.16	1,000,000	101,160,000		Oct 22 04:46 PM
Deerfield Private Design Fund	Stockholder	Oct 22 '24	Proposed Sale	101.16	1,000,000	101,160,000		Oct 22 04:44 PM
Porter James Richard	President and CEO	Oct 15 '24	Option Exercise	27.85	27,000	751,950	215,113	Oct 17 04:45 PM
Porter James Richard	President and CEO	Oct 15 '24	Sale	102.28	27,000	2,761,631	188,113	Oct 17 04:45 PM
James Richard Porter	Officer	Oct 15 '24	Proposed Sale	102.38	81,000	8,292,780		Oct 15 04:23 PM
Noci Darlene	Chief Development Officer	Oct 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Oct 02 05:34 PM
Noci Darlene	Chief Development Officer	Oct 01 '24	Sale	101.74	5,000	508,718	33,300	Oct 02 05:34 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '24	Option Exercise	27.85	10,000	278,500	43,300	Oct 02 05:33 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '24	Sale	101.06	10,000	1,010,620	33,300	Oct 02 05:33 PM
Darlene Noci	Officer	Oct 01 '24	Proposed Sale	101.19	10,000	1,011,900		Oct 01 04:16 PM
Alexandra Balcom	Officer	Sep 30 '24	Proposed Sale	102.12	30,000	3,063,600		Sep 30 04:12 PM
Shair Matthew	Director	Sep 23 '24	Sale	102.75	2,000	205,500	226,522	Sep 25 04:44 PM
Pelish Henry E.	Chief Scientific Officer	Sep 16 '24	Sale	98.92	32,795	3,244,140	33,300	Sep 18 04:53 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Option Exercise	18.93	8,000	151,440	41,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Sale	96.47	8,000	771,798	33,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Option Exercise	6.89	3,000	20,670	36,300	Sep 11 04:55 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Sale	88.18	3,000	264,546	33,300	Sep 11 04:55 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Option Exercise	18.93	5,000	94,650	38,300	Sep 04 07:52 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Sale	84.43	5,000	422,146	33,300	Sep 04 07:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Option Exercise	27.85	10,000	278,500	43,300	Sep 04 04:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Sale	84.23	10,000	842,349	33,300	Sep 04 04:52 PM
Shair Matthew	Director	Aug 26 '24	Sale	84.46	2,000	168,914	228,522	Aug 27 04:51 PM
Pelish Henry E.	Chief Scientific Officer	Aug 23 '24	Sale	85.08	10,500	893,340	66,095	Aug 27 04:49 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Option Exercise	23.80	11,000	261,750	44,300	Aug 27 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Sale	85.04	11,000	935,440	33,300	Aug 27 04:47 PM
Conley Emily	Director	Aug 23 '24	Option Exercise	13.79	3,334	45,976	5,841	Aug 27 04:44 PM
Conley Emily	Director	Aug 23 '24	Sale	85.02	3,334	283,457	2,507	Aug 27 04:44 PM
Henry Pelish	Chief Scientific Officer	Aug 23 '24	Proposed Sale	84.13	43,295	3,642,408		Aug 23 04:07 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Aug 09 04:48 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Sale	68.78	3,000	206,348	33,300	Aug 09 04:48 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Aug 02 04:45 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Sale	77.22	5,000	386,125	33,300	Aug 02 04:45 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Option Exercise	27.85	10,000	278,500	43,300	Aug 02 04:43 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Sale	79.51	10,000	795,074	33,300	Aug 02 04:43 PM
Shair Matthew	Director	Jul 29 '24	Sale	79.59	2,000	159,176	230,522	Jul 31 04:46 PM
Matthew Shair	Director	Jul 29 '24	Proposed Sale	81.68	8,000	653,440		Jul 29 04:09 PM
Conley Emily	Director	Jul 15 '24	Option Exercise	13.79	5,000	68,950	7,507	Jul 16 04:47 PM
Conley Emily	Director	Jul 15 '24	Sale	80.72	5,000	403,621	2,507	Jul 16 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Option Exercise	27.85	6,000	167,100	39,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Sale	80.16	6,000	480,960	33,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Jul 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Sale	73.23	3,000	219,687	33,300	Jul 10 04:45 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Jul 02 04:47 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Sale	75.54	5,000	377,696	33,300	Jul 02 04:47 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Option Exercise	27.85	10,000	278,500	43,300	Jul 02 04:44 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Sale	75.43	10,000	754,341	33,300	Jul 02 04:44 PM
Shair Matthew	Director	Jun 24 '24	Sale	80.22	2,000	160,438	232,522	Jun 26 04:54 PM
Conley Emily	Director	Jun 14 '24	Option Exercise	13.79	5,000	68,950	7,507	Jun 18 04:15 PM
Conley Emily	Director	Jun 14 '24	Sale	77.56	5,000	387,776	2,507	Jun 18 04:15 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Option Exercise	14.41	8,000	115,320	41,300	Jun 07 04:44 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Sale	80.40	8,000	643,213	33,300	Jun 07 04:44 PM
Shair Matthew	Director	May 28 '24	Sale	67.22	2,000	134,438	234,522	May 29 04:43 PM
Conley Emily	Director	May 15 '24	Option Exercise	12.31	5,000	61,565	5,008	May 17 04:41 PM
Conley Emily	Director	May 15 '24	Sale	69.09	5,000	345,450	8	May 17 04:41 PM
Shair Matthew	Director	May 13 '24	Sale	65.84	37,500	2,468,866	1,424,698	May 15 04:54 PM
Shair Matthew	Director	May 06 '24	Sale	69.48	37,500	2,605,525	1,462,198	May 08 04:51 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Option Exercise	6.89	3,000	20,670	36,300	May 03 04:47 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Sale	72.07	3,000	216,203	33,300	May 03 04:47 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	37,500	2,531,537	1,499,698	May 01 04:41 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	2,000	135,018	236,522	May 01 04:41 PM
Shair Matthew	Director	Apr 22 '24	Sale	63.65	37,500	2,386,910	1,537,198	Apr 24 04:44 PM
Shair Matthew	Director	Apr 15 '24	Sale	65.56	37,500	2,458,335	1,574,698	Apr 17 04:46 PM
Conley Emily	Director	Apr 15 '24	Option Exercise	9.36	5,000	46,800	5,008	Apr 17 04:44 PM
Conley Emily	Director	Apr 15 '24	Sale	65.52	5,000	327,607	8	Apr 17 04:44 PM
Shair Matthew	Director	Apr 08 '24	Sale	68.44	37,500	2,566,479	1,612,198	Apr 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Option Exercise	6.89	3,000	20,670	36,300	Apr 05 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Apr 04 '24	Sale	73.60	3,000	220,787	33,300	Apr 05 04:47 PM
Shair Matthew	Director	Apr 01 '24	Sale	76.92	37,500	2,884,337	1,649,698	Apr 03 04:45 PM
Hack Andrew A. F.	Director	Mar 27 '24	Sale	72.77	880,000	64,035,959	2,697,267	Mar 29 05:15 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Option Exercise	22.58	22,000	496,740	55,300	Mar 29 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Mar 28 '24	Sale	75.20	22,000	1,654,311	33,300	Mar 29 04:46 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	37,500	2,878,982	1,687,198	Mar 27 04:55 PM
Shair Matthew	Director	Mar 25 '24	Sale	76.77	2,000	153,546	238,522	Mar 27 04:55 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Option Exercise	7.74	20,000	154,800	53,300	Mar 25 04:49 PM
Noci Darlene	Chief Development Officer	Mar 22 '24	Sale	77.51	20,000	1,550,229	33,300	Mar 25 04:49 PM
Conley Emily	Director	Mar 15 '24	Option Exercise	9.36	13,333	124,797	13,341	Mar 19 04:46 PM
Conley Emily	Director	Mar 15 '24	Sale	80.92	13,333	1,078,883	8	Mar 19 04:46 PM
Shair Matthew	Director	Dec 26 '23	Sale	75.12	69,602	5,228,346	1,774,246	Dec 28 05:09 PM
Shair Matthew	Director	Dec 28 '23	Sale	75.46	48,548	3,663,492	1,724,698	Dec 28 05:09 PM
Shair Matthew	Director	Dec 27 '23	Sale	75.17	1,000	75,170	1,773,246	Dec 28 05:09 PM
Protopapas Anna	Director	Dec 18 '23	Option Exercise	9.36	5,000	46,800	5,000	Dec 20 04:58 PM
Protopapas Anna	Director	Dec 18 '23	Sale	75.67	5,000	378,350	0	Dec 20 04:58 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Option Exercise	4.70	40,000	188,139	40,000	Dec 20 04:56 PM
Noci Darlene	Chief Development Officer	Dec 18 '23	Sale	75.82	40,000	3,032,800	0	Dec 20 04:56 PM
Miller Deborah Ann	Chief Legal Officer	Dec 18 '23	Option Exercise	27.85	33,046	920,331	33,046	Dec 20 04:54 PM
Miller Deborah Ann	Chief Legal Officer	Dec 19 '23	Option Exercise	18.93	5,000	94,650	5,000	Dec 20 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUVL

Nuvalent Inc

Upgrade your FINVIZ experience